Myriad Genetics (STU:MYD) Interest Expense: €-11.8 Mil (TTM As of Mar. 2026)

What is Myriad Genetics Interest Expense?

Myriad Genetics STU:MYD -4.18% 53 Interest Expense is €-11.8 Mil as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 53/100 and a GF Value™ of €13.07 (Possible Value Trap). The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Myriad Genetics's interest expense for the three months ended in Mar. 2026 was € -3.5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-11.8 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Myriad Genetics's Operating Income for the three months ended in Mar. 2026 was € -21.9 Mil. Myriad Genetics's Interest Expense for the three months ended in Mar. 2026 was € -3.5 Mil. Myriad Genetics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Myriad Genetics (STU:MYD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Myriad Genetics's Interest Expense for the three months ended in Mar. 2026 was €-3.5 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-21.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €176.8 Mil.

Myriad Genetics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Myriad Genetics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Myriad Genetics Interest Expense Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's Interest Expense can be seen below:

Myriad Genetics Interest Expense Chart

Myriad Genetics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-5.84

-3.02

-2.66

-2.67

-8.97

Myriad Genetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Interest Expense	Get a 7-Day Free Trial															-0.74	-1.30	-3.24	-3.76	-3.55

53GF Score

Myriad Genetics Inc STU:MYD

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Myriad Genetics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-11.8 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of €-11.8 Mil mean?

Myriad Genetics (STU:MYD) has a Interest Expense of €-11.8 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Myriad Genetics and its competitors.

Is Myriad Genetics' Interest Expense too high?

Myriad Genetics' current Interest Expense is €-11.8 Mil. Overall, Myriad Genetics has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Myriad Genetics' Interest Expense compare to FLGT and CSTL?

Myriad Genetics' Interest Expense of €-11.8 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Medical Diagnostics & Research company?

A good Interest Expense depends on the Medical Diagnostics & Research industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current Interest Expense is €-11.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Myriad Genetics stock overvalued right now?

Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.07, compared to a current price of €5.09 — trading 61% below its estimated fair value. The current Interest Expense is €-11.8 Mil. Myriad Genetics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current Interest Expense is €-11.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.09 is trading 61% below its estimated GF Value™ of €13.07. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

Interest Expense: €-11.8 Mil
GF Value™: €13.07 vs. price of €5.09 (61% below fair value)
GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies FLGT CSTL BDSX IMDX XGN BNR IDXG PRPO QUCY BIOQ TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges MYGN:USA 0K3W:UK MYD:Germany

Address 322 North 2200 West, Salt Lake City, UT, USA, 84116

Website https://www.myriad.com

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

53GF Score

Get the complete analysis for STU:MYD

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.09

Price

€13.07

GF Value

View STU:MYD Analysis

See Interest Expense data for all stocks →